Targeting dormant leukaemia cells
Nature
2008년5월12일
A new role for a protein involved in leukaemia is described in Nature this week; the research demonstrates its potential as a therapeutic target to eradicate dormant leukaemia-initiating cells.
The promyelocytic leukaemia protein (PML) tumour suppressor is known to be involved in the development of some forms of leukaemia. Pier Paolo Pandolfi and colleagues identify a new and unexpected role for PML in the maintenance of both haematopoietic stem cells and leukaemia-initiating cells. They demonstrate, in mice, that targeting the protein with arsenic trioxide eliminates the cancer-initiating cells, thought to be resistant to chemotherapy and other therapies.
The team believes that their results present a new pharmacological approach to target cells that are missed by other therapies and therefore lead to disease relapse.
doi: 10.1038/nature07016
리서치 하이라이트
-
3월4일
Environment: Reservoirs account for more than half of water storage variabilityNature
-
3월2일
Evolution: Neanderthals may have heard just like usNature Ecology & Evolution
-
3월2일
Geoscience: Earth’s atmosphere may return to low-levels of oxygen in one billion yearsNature Geoscience
-
2월26일
Environment: Shifting from small to medium plastic bottles could reduce PET wasteScientific Reports
-
2월24일
Environment: European forests more vulnerable to multiple threats as climate warmsNature Communications
-
2월11일
Environment: Global CFC-11 emissions in declineNature
